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Abstract
Introduction: 17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently
in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than
shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS) and spectroscopic
imaging (MRSI) are noninvasive imaging methods than can be used to monitor metabolic biomarkers of drug-
target modulation. This study set out to examine the MRS-detectable metabolic consequences of Hsp90 inhibition
in a breast cancer model.
Methods: MCF-7 breast cancer cells were investigated, and MRS studies were performed both on live cells and on
cell extracts.
31P and
1H MRS were used to determine total cellular metabolite concentrations and
13C MRS was
used to probe the metabolism of [1,2-
13C]-choline. To explain the MRS metabolic findings, microarray and RT-PCR
were used to analyze gene expression, and in vitro activity assays were performed to determine changes in
enzymatic activity following 17-AAG treatment.
Results: Treatment of MCF-7 cells with 17-AAG for 48 hours caused a significant increase in intracellular levels of
choline (to 266 ± 18% of control, P = 0.05) and phosphocholine (PC; to 181 ± 10% of control, P = 0.001) associated
with an increase in expression of choline transporter SLC44A1 and an elevation in the de novo synthesis of PC. We
also detected an increase in intracellular levels of glycerophosphocholine (GPC; to 176 ± 38% of control, P = 0.03)
associated with an increase in PLA2 expression and activity.
Conclusions: This study determined that in the MCF-7 breast cancer model inhibition of Hsp90 by 17-AAG results
in a significant MRS-detectable increase in choline, PC and GPC, which is likely due to an increase in choline
transport into the cell and phospholipase activation.
1H MRSI can be used in the clinical setting to detect levels of
total choline-containing metabolite (t-Cho, composed of intracellular choline, PC and GPC). As Hsp90 inhibitors
enter routine clinical use, t-Cho could thus provide an easily detectable, noninvasive metabolic biomarker of Hsp90
inhibition in breast cancer patients.
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Recent reports from the American Cancer Society indicate
that nearly 1 in 8 American women will be diagnosed with
breast cancer in her lifetime. As the prevalence of this dis-
ease persists, the pressure to develop novel and improved
therapies increases. Cancer research has become increas-
ingly focused on the potential of various small molecule
inhibitors to target specific proteins in signaling pathways
that are commonly overexpressed in cancer. Whereas
these drugs have had some success in clinical trials, they
still have limited efficacy in treating many cancer types
and this has been largely due to cross-talk between differ-
ent pathways, feedback loops, and parallel signaling [1].
This challenge might be overcome by simultaneously
inhibiting several oncogenic pathways; 17-allyamino-17-
demethoxygeldanamycin (17-AAG), a small molecule
inhibitor of heat shock protein 90 (Hsp90), accomplishes
this. Hsp90 is a molecular chaperone responsible for the
folding and stability of multiple client proteins, many of
which are oncogenes, including Akt, c-Raf, and Her-2
[2]. When 17-AAG inhibits Hsp90, its client proteins
are degraded via the proteasome ubiquinitation pathway,
resulting in inhibition of oncogenic signaling. High
expression of Hsp90 has also been associated with
decreased survival in breast cancer [3]. Hsp90 inhibitors,
including 17-AAG, are currently undergoing clinical
trials and show promise as effective anti-cancer thera-
pies for the treatment of many cancer types, including
breast cancer [4,5]. However, the treatment of tumors
with 17-AAG most often results in an inhibition of
tumor growth rather than shrinkage [6-8]. As a result,
early response to this type of treatment is nearly impos-
sible to detect by traditional imaging, such as computed
tomography and magnetic resonance (MR) imaging. As
this therapy enters routine clinical use, it would be ben-
eficial to have a noninvasive functional or metabolic bio-
marker that could provide information about the
molecular effects of Hsp90 inhibition in patients.
Magnetic resonance spectroscopy (MRS)-detectable
phosphocholine (PC) could potentially serve as such a
biomarker. Concentrations of PC and, in some cases,
GPC are elevated in tumors as compared with normal
tissue and have been shown to increase with increasing
malignancy in breast cancer models and patient studies
[9-15]. Accordingly, PC and total choline-containing
metabolites (t-Cho) (composed of choline, PC, and gly-
cerophosphocholine [GPC] and detectable by
1Hm a g -
netic resonance spectroscopic imaging [MRSI]) are now
recognized as clinically relevant metabolic biomarkers of
breast cancer [14,16,17]. Additionally,
31Pa n d
1HM R S
studies have demonstrated that PC and t-Cho levels
decrease in response to chemotherapy as well as tar-
geted therapies, both in vitro and in vivo [18-28].
However, a previous MRS-based study examining the
effects of 17-AAG in a colon cancer model reported the
somewhat atypical effect of increases in PC and GPC
concentrations following response to treatment [29].
This finding was supported by a different positron emis-
sion tomography (PET)-based study, which reported an
increase in uptake of the PET tracer [
11C]-choline after
treatment with Hsp90 inhibitor NVP-AUY922 in three
different cell lines (MCF-7 human breast cancer, U87MG
human glioblastoma, and HCT116 human colon cancer)
[30]. GPC levels have been shown to increase in response
to other anti-cancer drug treatments [31-33].
The concentration of PC in the cell is regulated by the
enzymes of the choline phospholipid metabolic pathway
(Figure 1). Extracellular choline is actively transported
into the cell by several choline transporters and subse-
quently is phosphorylated to PC by choline kinase
(ChoK) [34,35]. CTP:phosphocholine cytidylyltransferase
(CCT) metabolizes PC to cytidine diphosphate-choline
(CDP-choline). Diacylglycerol cholinephosphotransferase
(CPT) further metabolizes CDP-choline to one of the
main membrane phospholipids, phosphatidylcholine
(PtdCho), and CCT is considered the rate-limiting step
for PtdCho synthesis [36]. Various phospholipase
enzymes can break down PtdCho: phospholipases
A1 and A2 (PLA1 and PLA2) generate fatty acids and
Figure 1 Schematic of choline phospholipid metabolism.
Schematic drawing of choline phospholipid metabolism and its
regulatory enzymes illustrates the metabolic reactions associated
with modulation of choline-containing metabolites. CCT, CTP:
phosphocholine cytidylyltransferase; CDP-choline, cytidine
diphosphate-choline; ChoK, choline kinase; CPT, diacylglycerol
cholinephosphotransferase; GDPD, glycerophosphocholine
phosphodiesterase; GPC, glycerophosphocholine; LPL,
lysophospholipase; PC, phosphocholine; PLA, phospholipase A; PLC,
phospholipase C; PLD, phospholipase D; PtdCho,
phosphatidylcholine.
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further metabolized by lysophospholipase into fatty
acids and GPC; phospholipase C (PLC) generates PC
and diacylglycerol; and phospholipase D (PLD) generates
choline and phospahtidic acid. GPC can be further
metabolized by glycerophosphocholine phosphodiester-
ase (GDPD) into choline. Examination of this pathway
reveals three sources that could be responsible for
increased PC following 17-AAG treatment: an increase
in the de novo synthesis of PC from extracellular cho-
line, a decrease in the further metabolism of PC via
CCT, or an increase in the breakdown of PtdCho.
Since 17-AAG is currently in clinical trials in patients
with breast cancer [4,5], we set out to determine
whether PC and t-Cho can serve as noninvasive biomar-
kers of Hsp90 inhibition in this group of patients. Our
goals were, first, to confirm that treatment with 17-
AAG results in increases in PC and t-Cho and, second,
to investigate the underlying mechanism of their modu-
lation. We studied the effect of 17-AAG treatment on
the MCF-7 breast cancer cell line by probing choline
metabolism by means of MRS and by using complemen-
tary assays to determine the activity and expression of
the enzymes involved in choline phospholipid metabo-
lism. We found that 17-AAG caused increases in the
intracellular choline and PC concentrations, likely
resulting from increased expression of the choline trans-
porter SLC44A1 and elevation in the de novo synthesis
of PC. We also found that GPC levels were elevated
with 17-AAG treatment, resulting from increases in
gene expression and activity of PLA2.
Materials and methods
Cell culture
MCF-7 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA) via UCSF Cell
Culture Facility (San Francisco, CA, USA). Cells were
cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM L-glutamine, 100 units/mL penicil-
lin, and 100 μg/mL streptomycin (UCSF Cell Culure
Facility). Custom-made DMEM with 0.22 g/L inorganic
phosphate (UCSF Cell Culture Facility) was used for all
MRS experiments. For inhibition of Hsp90, 3 μM1 7 -
AAG (LC Laboratories, Woburn, MA, USA) was added
to the culture medium for a period of 48 hours. Med-
ium was replenished with fresh 17-AAG every 24 hours
during treatment. The doubling time of logarithmic-
phase MCF-7 cells growing in tissue culture flasks or
on beads was determined by seeding at a density of 1 ×
10
6 cells per 75-cm
2 flask or at a density of 3 × 10
6
cells per 0.5 mL of beads, trypsinizing at 24-hour inter-
vals and counting the number of cells by using a
hemocytometer.
Cell proliferation assay
The effect of 17-AAG treatment on cell proliferation
was determined by using the WST-1 cell proliferation
assay (Roche, Indianapolis, IN, USA). Cells were seeded
in 96-well microplates (1.5 × 10
6 cells per well in 150
μL of culture medium), and control and 17-AAG-treated
cells were probed at different time periods between 4
and 48 hours. For this, cells were incubated for 1 hour
with WST-1 reagent, and cell viability was determined
by quantification of the absorbance at 440 nm by using
a plate reader spectrophotometer (Tecan, Grödig,
Austria).
Protein determination
Protein concentrations per cell were determined in cells
lysed in Cell Lysis Buffer (Cell Signaling Technology,
Danvers, MA, USA) by using a Coomassie Plus-The Bet-
ter Bradford™ Assay Kit (Pierce, Rockford, IL, USA), and
bovine serum albumim was used as a protein standard.
Absorbance was measured at 595 nm by using a plate
reader spectrophotometer (Tecan).
Western blotting
The effect of 17-AAG on levels of client proteins was
analyzed by Western blotting. Cellular lysates were
extracted in Cell Lysis Buffer (Cell Signaling Technol-
ogy) with added Protease Inhibitor (Calbiochem, now
p a r to fE M DB i o s c i e n c e s ,I n c . ,S a nD i e g o ,C A ,U S A ) .
Protein concentration was determined by using a Coo-
massie Plus Protein Assay (Pierce). Approximately 30 μg
of protein was loaded into 4% to 20% SDS-PAGE gels
(Bio-Rad Laboratories, Hercules, CA, USA). Gels were
run for 30 minutes and then proteins were electrotrans-
ferred onto nitrocellulose membranes. Membranes were
blocked for 1 hour in 5% milk in TBST (Tris-buffered
saline Tween 20) and then incubated overnight with pri-
mary antibodies against Akt, c-Raf, and Actin (Cell Sig-
naling Technology), and Actin was used as a loading
control. After incubation for 2 hours with secondary
antibody anti-IgG horseradish peroxidase-linked anti-
body (Cell Signaling Technology), the immunocom-
plexes were visualized with ECL Western Blotting
Substrate (Pierce).
Flow cytometry
Cells (1 × 10
6)w e r es e e d e di n7 5 - c m
2 tissue culture
flasks in 10 mL of culture medium. Following treatment,
approximately 2 × 10
6 cells were harvested by trypsini-
zation, washed with phosphate-buffered saline (PBS),
and fixed in 70% ethanol. Fixed cells were incubated
with RNase A at 100 units/mL (Sigma-Aldrich, St.
Louis, MO, USA) for 30 minutes, washed with PBS, and
then stained with propidium iodide at 20 μg/mL
(Sigma-Aldrich) for 30 minutes. Cells were counted with
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cytometer and CellQuest Pro software (BD Biosciences,
Mountain View, CA, USA) and single cells were gated
away from clumped cells by using forward light scatter-
ing on an FL2-width versus FL2-area dot plot. The per-
centages of cells in the G1,S ,a n dG 2/M phases were
determined by plotting a histogram of FL2-A. The rela-
tive cell sizes of the G1,S ,a n dG 2/M phase populations
of control and 17-AAG-treated cells were determined by
using forward scattering height (FSC-H).
Perfused cell magnetic resonance spectroscopy studies
Approximately 4 × 10
7 MCF-7 cells were grown on Biosi-
lon microcarrier beads (Nunc, Rochester, NY, USA) in
order to be loaded into a perfusion system for MRS stu-
dies as described previously [37]. Cells were seeded on the
microcarrier beads, allowed to attach for 24 hours, and
then treated for 48 hours prior to the MR experiment. To
monitor a similar number of cells during MRS acquisition,
control cells were seeded at a density of approximately 5 ×
10
6 cells/mL of beads and 17-AAG-treated cells were
seeded at a density of approximately 9 × 10
6 cells/mL of
beads. To obtain cell counts for both the start and end of
the experiment, an additional set of cells was seeded on
beads for each experiment and treated in a fashion identi-
cal to those loaded into the perfusion system.
MRS studies were performed on a 500-MHz INOVA
spectrometer (Varian, Santa Clara, CA, USA). Compo-
site pulse proton-decoupled
31P spectra were first
acquired to confirm cell viability and quantify metabolite
levels.
31P spectra were acquired with a 30° pulse and 3-
second relaxation delay and 1,000 transients for a total
acquisition time of 70 minutes. Cells were then perfused
with fresh culture medium containing only 56 μM [1,2-
13C]-choline (Cambridge Isotope Laboratories, Andover,
MA, USA) and no unlabeled choline for a period of 14
hours. Proton-decoupled (Waltz 16)
13C spectra were
acquired during that time in 2-hour intervals by using a
60° pulse and 6-second relaxation delay and 1,024 tran-
sients. Spectra were quantified with ACD/Spec Manager
version 9.15 software (Advanced Chemistry Develop-
ment, Toronto, ON, Canada). Peak integrals obtained by
deconvolution were normalized to cell number and to a
metabolite of known concentration in the culture med-
ium (1.87 μM inorganic phosphate [Pi]f o r
31Ps p e c t r a
and 5 mM [1-
13C]-glucose [Cambridge Isotope Labora-
tories] for
13C spectra). Data were corrected for satura-
tion effects by using correction factors obtained from a
fully relaxed spectrum of perfused cells (fully relaxed
13C spectra were acquired with a 90°, 20-microsecond
pulse and 30-second relaxation delay for 1,024 transi-
ents, and fully relaxed
31P spectra were acquired with a
90°, 22-microsecond pulse and 30-second relaxation
delay for 1,000 transients).
Cell extracts
Cells were grown in culture with medium in which all
glucose and choline were completely replaced by 5 mM
[1-
13C]-glucose and 56 μM [1,2-
13C]-choline (Cambridge
Isotope Laboratories) for a period of 48 hours prior to
extraction. Approximately 7 × 10
7 cells were extracted
by means of the dual-phase extraction method, as
described previously [26,38,39]. Briefly, cultured cells
were collected by trypsinization, counted to obtain cell
number, and fixed in 10 mL of methanol. Chloroform
(10 mL) was added and then water (10 mL) was as well.
The solution was vortexed and centrifuged to separate
the lipid and aqueous phases and then each phase was
collected separately. Solvents were lyophilized off each
sample. Aqueous samples were re-dissolved in a volume
of 400 μL of deuterium oxide, and lipid samples were
re-dissolved in 500 μL of deuterated chloroform-metha-
nol mixture.
13C,
1H, and
31P spectra were acquired on the lipid
and aqueous portions of the cell extracts by using a
600-MHz INOVA spectrometer (Varian) equipped with
a 5-mm broadband observe probe. Proton-decoupled
(Waltz 16)
13C and
31P spectra were acquired with a 30°
pulse and 3-second relaxation delay.
13C aqueous spec-
tra were acquired for 5,000 transients and a total acqui-
sition time of 6 hours.
13C lipid spectra were acquired
for 2,500 transients and a total acquisition time of 3
hours.
31P aqueous and lipid spectra were acquired for
2,500 transients and a total acquisition time of 3 hours.
1H spectra were acquired with a 90° pulse and 3-second
relaxation delay and 256 transients for a total acquisi-
tion time of 25 minutes. Spectra were quantified with
ACD/Spec Manager version 9.15 software (Advanced
Chemistry Development). Peak integrals obtained by
deconvolution were normalized to an external standard
(100 mM trimethylsilyl propionate [TSP] [Sigma-
Aldrich] for
13C spectra and 10 mM methylene dipho-
sphoric acid [MDPA] [Sigma-Aldrich] for
31P spectra)
and to cell number and corrected for saturation effects
by using data obtained from fully relaxed spectra of cell
extracts as described above. In addition, studies were
performed with choline concentration at the normal
concentration in human plasma. For this, cells were
grown with a 10 μM choline concentration in the med-
ium, and cell extracts and MRS experiments were per-
formed as above.
Microarray analysis of gene expression
Total cellular RNA was isolated from approximately 1 ×
10
7 cells after 48 hours of treatment with 17-AAG or
vehicle (dimethyl sulfoxide) by using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) in accordance with the
instructions of the manufacturer. RNA quality was
determined by Bioanalyzer (Agilent Technologies, Santa
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values of at least 8.0 were considered acceptable (most
values were 9.5 or higher). Microarray hybridization was
performed at the UCSF Genomics Core Laboratories
(UCSF/Gladstone, San Francisco, CA, USA) by using the
Human Gene 1.0 ST. Human Gene 1.0ST was analyzed
by fluorescence detection by using the Agilent GeneAr-
ray Scanner (Agilent Technologies). Data acquisition
was performed with Micro Array Suite 5.0 software
(Affymetrix, Santa Clara, CA, USA). Microarray experi-
ments were performed with four repeats of each condi-
tion. Microarray data are available through the
ArrayExpress public repository [EMBL:E-MTAB-339] in
compliance with the standards of the Microarray Data
Gene Expression Society.
Reverse transcription-polymerase chain reaction analysis
of gene expression
An RNeasy Mini Kit (Qiagen) was used to extract total
cellular RNA from samples. Total RNA concentration of
samples was determined by using an ND1000 Fluoros-
pectrometer (NanoDrop Technologies, Wilmington, DE,
USA). The QuantiTect Reverse Transcription kit (Qia-
gen) was used to perform reverse transcription. Reverse
transcription-polymerase chain reaction (RT-PCR) was
performed on the resulting cDNA on a Taqman 7900
(Applied Biosystems, Carlsbad, CA, USA). Expressions
of ChoKa,C h o K b,a n dS L C 4 4 A 1w e r ee x a m i n e dw i t h
Assays-on-Demand (Applied Biosystems) and normal-
ized to the expression of the 18S ribosomal subunit
(Integrated DNA Technologies, Coralville, IA, USA).
Choline kinase activity assay
ChoK activity was measured in cell extracts by
1HM R S
as previously described [40]. In brief, approximately 1 ×
10
7 cells were resuspended in 500 μL of lysis buffer con-
taining 100 mM Tris (pH 8.0), 1 mM ethylenediamine-
tetraacetic acid (EDTA), and 10 mM dithiothreitol
(DTT) (all chemicals from Sigma-Aldrich). Lysate was
repeatedly passaged through a fine-tipped needle (27.5-
gauge) for homogenization and was sonicated 10 × 1 s
at 20 kHz for membrane solubilization. The homogenate
was centrifuged at 16,000 rpm for 30 minutes at 4°C,
and 100 μL of reaction buffer containing 100 mM Tris
(pH 8.0), 60 mM choline chloride, 120 mM ATP, and
120 mM magnesium chloride (all chemicals from
Sigma-Aldrich) at the final concentration were added to
the lysate supernatant. MRS experiments were per-
formed at 25°C on a 600-MHz INOVA spectrometer
(Varian). The conversion of choline to PC was measured
in an array of
1H spectra over a 1-hour period.
1H spec-
tra were obtained with a 90° pulse and 3-second relaxa-
tion delay. Choline and PC concentrations were
determined as peak areas, and ChoK activity was
determined by linear regression analysis of points in the
linear portion of the curve representing the time course
of PC formation.
CTP:PC cytidylyltransferase activity assay
This assay was based on the method outlined by Vance
and colleagues [41] in 1981 but with substantial modifi-
cations for compatibility with MRS. In brief, 2 × 10
7 cells
were resuspended in 540 μL of lysis buffer containing 50
mM HEPES (pH 7.0) (Sigma-Aldrich), 5 mM EDTA
(Sigma-Aldrich), 5 mM EGTA (ethylene glycol tetraacetic
acid) (Sigma-Aldrich), 5.5 mM sodium bisulfite (Sigma-
Aldrich), and 1 μL/mL protease inhibitor cocktail (Cal-
biochem). Lysate was repeatedly passaged through a fine-
tipped needle (27.5-gauge) for homogenization and was
sonicated 10 × 1 s at 20 kHz for membrane solubiliza-
tion. The homogenate was centrifuged at 16,000 rpm for
30 minutes at 4°C. The cytidylyltransferase activity of the
supernatant fraction was measured immediately after the
addition of 60 μL of reaction mixture (final concentra-
tions: 50 mM Tris-HCl [pH 8.0], 10 mM cytidine tripho-
sphate [CTP], 5 mM PC, 5 mM DTT, and 25 mM
MgCl2) (all chemicals from Sigma-Aldrich). MRS experi-
ments were performed at 33°C on the 600-MHz INOVA
spectrometer (Varian). Proton-decoupled (Waltz 16)
31P
MR spectra were obtained with 30° pulse and 2.6-second
repetition time. PC and CDP-choline concentrations
were determined from peak areas. Cytidylyltransferase
activity was determined by linear regression analysis of
points in the linear portion of the curve representing the
time course of CDP-choline formation.
Phospholipase C activity assay
PtdCho-specific PLC activity was determined in cell
lysates by using the EnzChek Direct Phospholipase C
Assay (Invitrogen Corporation, Carlsbad, CA, USA). The
assay measures PLC activity by addition of a proprietary
substrate (glycero-phosphoethanolamine with a dye-
labeled sn-2 acyl chain), which is cleaved by PtdCho-
specific PLC. The cleavage releases the dye-labeled dia-
cylglycerol, which produces a positive fluorescence sig-
nal that can be measured. Fluorescence (485 nm
excitation and 535 nm emission) was measured by a
SpectroFluor Plus spectrofluorometer (Tecan).
Phospholipase A1/A2 activity assay
T h ea c t i v i t yo fP t d C h o - s p e c i f i cP L A 1a n dP L A 2
enzymes was determined in cell lysates by using the
EnzCheck Phospholipase A1 and Phospholipase A2
Assay kits (Invitrogen Corporation). The assay measures
PLA1 activity by the addition of a proprietary substrate
(dye-labeled glycerophosphoethanolamines with BOD-
IPY FL dye-labeled acyl chain at the sn-1 position and
dinitrophenyl quencher-modified head group). The sn-1
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releases the dye-labeled acyl chain and produces a posi-
tive fluorescence signal that can be measured. The
PLA2 activity assay measures the sn-2e s t e rl i n kh y d r o -
lysis of the proprietary substrate 1-O-(6-BODIPY 558/
568-aminohexyl)-2-BODIPY FL C5-Sn-glycero-3-phos-
phocholine by PLA2 enzyme, which releases the dye-
labeled portion and produces a positive fluorescent sig-
nal that can be measured. Fluorescence (505 nm excita-
tion and 515 nm emission) was measured by a
SpectroFluor Plus spectrofluorometer (Tecan).
Statistical analysis
The two-tailed Student t test was used to determine the
statistical significance of the results, and a P value of
not more than 0.05 was considered significant. All
results are expressed as mean ± standard deviation.
Results
17-AAG treatment depletes Hsp90 client proteins and
inhibits cell proliferation
Because our studies involved investigations of cells
grown in flasks or on beads, we first confirmed that the
proliferation rate of the cells was unaffected by the cul-
ture conditions. MCF-7 cell cultures in 75-cm
2 flasks
had a doubling time of 29.5 ± 3.7 hours (n = 4) and this
was comparable to a doubling time of 32.8 ± 2.7 hours
for MCF-7 cells seeded on microcarrier beads (n =4 ,P
= 0.20). Of note, the doubling time of MCF-7 cells pro-
vided by the American Type Culture Collection (from
which the cells were obtained) is 29 hours and is consis-
tent with our findings. MCF-7 cells were treated for 48
hours with 3 μM 17-AAG. This led to the depletion of
the known Hsp90 client proteins total-Akt and c-Raf
(Figure 2a) and was associated with a decrease to 52% ±
3% in the number of cells as compared with control
(Figure 2b). To further investigate the effect of 17-AAG
treatment, FACS cell cycle analysis was performed after
treatment for 48 hours. The results showed that the
inhibitory effect of 17-AAG on cell proliferation is lar-
gely due to cell cycle arrest in the G2/M phase. The
fraction of cells in the G2 phase increased from 8.4% ±
4.2% in control cells to 44.7% ± 5.2% in 17-AAG-treated
cells (n =3 ,P = 0.0008). The fraction of cells in the S
phase decreased from 31.2% ± 2.3% in control cells to
4.6% ± 3.1% in 17-AAG-treated cells (n =3 ,P =
0.0005). The fraction of cells in G1 phase was not signif-
icantly altered by 17-AAG treatment, and values for this
fraction were 61% ± 5% in control cells and 51% ± 7%
in 17-AAG-treated cells (n =3 ,P =0 . 1 2 ) .C h a n g e si n
relative cell size with 17-AAG treatment were also
assessed. Whereas there was an increase in the size of
cells in the G1 and S phases with 17-AAG treatment,
there was a decrease in the size of cells in the G2/M
phase population. Thus, given the entire cell population,
the average cell size was not significantly altered, and
17-AAG-treated cells were 104% ± 4% the size of con-
trol cells (n =3 ,P = 0.26). Consistent with this finding,
average protein per cell was not significantly altered
with 17-AAG treatment, and these values were 2.76 ±
0.05 mg/10
7 cells in control cells and 2.88 ± 0.25 mg/
10
7 cells in 17-AAG-treated cells (n =3 ,P = 0.12).
17-AAG treatment leads to increased PC levels and
increased de novo PC synthesis
To assess the effects of 17-AAG treatment on choline
metabolism in live cells,
31Pa n d
13C MR spectra were
acquired from MCF-7 cells grown on beads and perfused
in a 10-mm NMR (nuclear magnetic resonance) tube
inside the spectrometer. First, a
31PM Rs p e c t r u mw a s
acquired in order to determine the total PC pool in both
control and 17-AAG-treated cells (Figure 3a). PC concen-
trations increased significantly to 180% ± 19% of control
in MCF-7 cells treated for 48 hours (n =3 ,P = 0.004).
Control cells had 19.3 ± 3.4 fmol/cell, and 17-AAG-treated
cells had 34.7 ± 2.8 fmol/cell. Additionally, the concentra-
tion of GPC increased significantly with 17-AAG
Figure 2 Effect of 17-AAG on cell proliferation and Hsp90 client
protein levels. (a) Western blot analysis showing depletion of Hsp90
client proteins total-Akt and c-Raf following 17-AAG treatment of
MCF-7 cells for 48 hours. Actin was used as a loading control. (b)
Results of WST-1 assay showing 17-AAG effects on MCF-7 cell
proliferation over a 48-hour treatment period. 17-AAG, 17-allyamino-
17-demethoxygeldanamycin; Hsp90, heat shock protein 90.
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cell in control cells to 5.5 ± 1.3 fmol/cell in 17-AAG-trea-
ted cells (n =3 ,P = 0.04). After 17-AAG treatment, there
was no significant change in the b-NTP levels, which were
104% ± 12% of control (n =3 ,P = 0.77).
The metabolism of live MCF-7 cells was then probed
in real time by replacing choline in the medium with
only [1,2-
13C]-choline and by using
13C MRS to monitor
the build-up of PC over a 14-hour period (Figure 3b).
The data curve obtained displays the build-up of
13C-
labeled PC inside the cells (Figure 3c). The level of
13C-
labeled PC after 14 hours of exposure to labeled sub-
strate was significantly higher in the cells treated with
17-AAG and increased with treatment to 171% ± 39%
of control, from 14.2 ± 2.5 fmol/cell to 24.3 ± 1.6 fmol/
cell (n =3 ,P = 0.007). Relative to the total PC concen-
trations determined from the
31P spectrum, 75% ± 17%
of the PC pool was
13C-labeled in control cells and 71%
± 10% of the pool was labeled in 17-AAG-treated cells
after 14 hours of labeling, with no significant difference
in percentage of labeling between control and treated
cells (n =3 ,P = 0.75).
At the end of the experiment, cells were extracted
directly from the beads in order to assess
13C-label
incorporation into PtdCho (owing to its low mobility
within the cell membrane, the lipid cannot be detected
in live cells) [38,39]. After 14 hours, less than 10% of
the PtdCho pool was
13C-labeled and no [1,2-
13C]-GPC
peak was observed in either the control or treated sam-
ples. We thus concluded that the build-up of [1,2-
13C]-
PC observed over the first 14 hours was due mainly to
the de novo synthesis of PC from extracellular labeled
choline rather than to PtdCho breakdown.
The initial rate of PC synthesis was linear over the
first 8 hours and was quantified for both control and
17-AAG-treated cells by using linear regression (R =
0.935 for control and R = 0.982 for treated). This analy-
sis showed that the initial rate of PC synthesis increased
significantly to 184% ± 7% of control with 17-AAG
treatment, from 1.2 ± 0.1 fmol/cell per hour in control
cells to 2.3 ± 0.4 fmol/cell per hour in treated cells (n =
3, P = 0.003). This increase was comparable to the
increase observed in the total PC pool (180% ± 19% of
control), indicating that increased de novo synthesis of
P Ci st h em a j o rc a u s eo fP Ce l e v a t i o nf o l l o w i n g1 7 -
AAG treatment.
17-AAG does not affect PtdCho levels but increases total
and de novo GPC and intracellular choline levels
1H,
31P, and
13C MRS were used to quantify cellular
metabolites in cell extracts following exposure to
[1,2-
13C]-choline for 48 hours in order to further confirm
the observations made in live cells and to monitor de
novo synthesis of PtdCho and GPC. Data from the
extracts confirmed the findings from live cells: after 48
hours of treatment with 17-AAG, the total PC levels
increased to 181% ± 10% relative to control, from 19.6 ±
1.2 to 35.4 ± 0.2 fmol/cell (n =3 ,P = 0.001) (Figure 4a),
and the de novo [1,2-
13C]-PC levels increased signifi-
cantly to 165% ± 10% of control, from 18.5 ± 1.6 fmol/
cell to 30.6 ± 2.7 fmol/cell (n =3 ,P = 0.006) (Figure 4b).
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Figure 3 Magnetic resonance spectroscopy detection of
increased total and de novo PC in live, perfused cells following
17-AAG treatment. (a)
31P spectra of live, perfused MCF-7 cells
illustrating an increase in PC after 48 hours of 17-AAG treatment. (b)
13C spectral array depicting the build-up of [1,2-
13C]-PC in perfused
MCF-7 cells over a 14-hour period. (c) Graph of build-up of de novo
[1,2-
13C]-PC in control (blue) and 17-AAG-treated (red) MCF-7 cells
over 14 hours of exposure to [1,2-
13C]-choline. The data represent
an average of three repeats. 17-AAG, 17-allyamino-17-
demethoxygeldanamycin; GPC, glycerophosphocholine; NTP,
nucleoside triphosphate; PC, phosphocholine; Pi, inorganic
phosphate; PPM, parts per million.
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Page 7 of 14Thus, after 48 hours of
13Cl a b e l i n g ,t h eP Cp o o lw a s
essentially fully
13C-labeled, with 94% ± 3% of the pool
labeled in control cells and 86% ± 11% of the pool labeled
in the treated cells and no significant difference in the
percentage of pool labeled between control and treated
cells (n =3 ,P = 0.20).
The concentration of total PtdCho was not changed
significantly by 17-AAG treatment, with 25.2 ± 4.1
fmol/cell in control cells and 26.3 ± 4.0 fmol/cell in 17-
AAG-treated cells (n =3 ,P = 0.75) (Figure 4c). De novo
synthesized [1,2-
13C]-PtdCho levels were not signifi-
cantly altered either. [1,2-
13C]-PtdCho levels in 17-
AAG-treated cells were 88% ± 11% of control, with 11.8
± 2.6 fmol/cell in control cells and 10.3 ± 0.9 fmol/cell
in 17-AAG-treated cells (n =3 ,P = 0.44). After 48
hours, there was 46% ± 3% incorporation of
13Cl a b e l
into the total PtdCho pool in control cells and there
was 40% ± 4% incorporation into the total pool in 17-
AAG-treated cells, with no significant difference in the
percentage of total PtdCho pool labeled between control
and treated cells (n =3 ,P = 0.06).
As in live cells, GPC levels increased significantly to
176% ± 38% relative to control (n =3 ,P = 0.03). Con-
trol cells had 4.4 ± 0.9 fmol/cell, and 17-AAG-treated
cells had 7.7 ± 1.3 fmol/cell (Figure 4a). De novo
GPC levels also significantly increased with 17-AAG
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Figure 4 Representative
31P,
13C, and
1H spectra of cell extracts. Representative spectra of control (bottom) and 17-AAG-treated (top) MCF-7
cells illustrate increased PC, intracellular choline, and GPC levels and unchanged PtdCho levels. (a)
13P spectra of the aqueous cell extract fraction
depicting an increase in total PC and GPC levels after treatment. (b)
13C spectra of the aqueous cell extract fraction depicting an increase in de
novo synthesized PC, GPC, and intracellular choline. (c)
31P spectra of the lipid cell extract fraction depicting constant PtdCho with 17-AAG
treatment. (d)
1H spectra of the aqueous cell extract fraction depicting an increase in the intracellular choline, PC, and GPC concentrations. 17-
AAG, 17-allyamino-17-demethoxygeldanamycin; GPC, glycerophosphocholine; NTP, nucleoside triphosphate; PC, phosphocholine; PCr,
phosphocreatine; Pi, inorganic phosphate; PPM, parts per million; PtdCho, phosphatidylcholine; PtdEth, phosphatidylethanol.
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Page 8 of 14treatment to 149% ± 15% of control, from 1.9 ± 0.1 to
2.8 ± 0.3 fmol/cell (n =3 ,P = 0.01) (Figure 4b). Of
note, the difference between GPC levels determined in
intact cells and in extracts was not significantly different
(P > 0.05). After 48 hours, there was 44% ± 11% incor-
poration of
13C label into the total GPC pool in control
cells and there was 37% ± 5% incorporation into the
t o t a lp o o li n1 7 - A A G - t r e a t e d cells, with no significant
difference in the percentage of total GPC pool labeled
between control and treated cells (n =3 ,P = 0.36).
The concentration of total intracellular choline was
determined by quantification of the
1H spectra (Figure
4d). Intracellular choline levels were significantly
increased following 17-AAG treatment to 266% ± 18% of
control, from 0.5 ± 0.1 fmol/cell in control cells to 1.3 ±
0.4 fmol/cell in treated cells (n =3 ,P =0 . 0 5 ) .C o n s i s t e n t
with these findings, intracellular [1,2-
13C]-choline (as
detected by
13C MRS; Figure 4b) was also increased in
treated cells to 220% ± 27% of control, from 0.6 ± 0.1
fmol/cell in control cells to 1.2 ± 0.3 fmol/cell in treated
cells (n =3 ,P = 0.05). Thus, after incubation with med-
ium containing [1,2-
13C]-choline for 48 hours, the intra-
cellular choline pool was essentially fully
13C-labeled.
There was 116% ± 53%
13C enrichment of the intracellu-
lar choline pool in control cells and there was 95% ± 38%
13C enrichment in treated cells, with no significant differ-
ence in percentage of enrichment between control and
treated cells (n =3 ,P = 0.6).
17-AAG causes modulation in gene expression and
activity of enzymes in the choline phosolipid metabolic
pathway
In an effort to interpret the metabolic findings, microar-
ray analysis was performed to determine the changes in
gene expression associated with Hsp90 inhibition that
could explain the alterations in choline metabolism
observed following 17-AAG treatment. Table 1 lists the
microarray data for enzymes involved in choline phos-
pholipid metabolism.
Choline transporters
Microarray analysis did not show significant changes in
t h eg e n ee x p r e s s i o no fc h o l i n et r a n s p o r t e r sS L C 5 A 7 ,
SLC22A1, or SLC22A2 but did show a significant
increase in the mRNA expression of the choline trans-
porter SLC44A1. RT-PCR confirmed the microarray
data, with a significant increase in SLC44A1 mRNA
levels to 169% ± 33% of control (n =4 ,P = 0.04).
Choline kinase
Microarray analysis did not show any significant change
in the expression of ChoK a or b mRNA levels. RT-
PCR was also performed to confirm the microarray data
a n dd i dn o ts h o was i g n i f i c a n tc h a n g ei nC h o K a or
ChoKb mRNA levels (n =4 ,P = 0.2). Finally, the cellu-
lar activity of ChoK remained essentially unchanged at
104% ± 23% of control; control cell extracts incubated
with choline produced 98 ± 15 fmol PC/cell per hour,
and 17-AAG-treated cells produced 102 ± 37 fmol PC/
cell per hour (n =4 ,P = 0.51).
CTP:PC cytidylyltransferase
Microarray analysis did not show any significant changes
in gene expression of the CCT isoenzymes. The activity of
CCT also remained unchanged with 17-AAG treatment at
107% ± 21% of control; control cell extracts incubated
with PC produced 18.2 ± 5.3 fmol CDP-choline/cell per
hour, and 17-AAG-treated cells produced 19.4 ± 4.3 fmol
CDP-choline/cell per hour (n =4 ,P = 0.74).
Phospholipases
Genes coding for PtdCho-specific PLC isoenzymes have
not yet been identified, preventing gene expression analy-
sis; however, PtdCho-specific PLC activity was assessed.
The PtdCho-specific PLC activity assay performed on cell
lysates showed a significant decrease in PLC activity with
17-AAG treatment to 66% ± 10% of control (n =3 ,P =
0.02). Although there are many PLA isoenzymes, expres-
sion of PLA2G6, PLA2G10, PLA2G15, and PLA2G16 (all
of which have activity on PtdCho) increased. Furthermore,
the PtdCho-specific PLA1 and PLA2 enzyme activity
assays did not find a significant increase in PLA1 activity
but did show a significant increase in PLA2 activity to
122% ± 5% of control (n =3 ,P = 0.02). Finally, microarray
data reported an increase in PtdCho-specific PLD1 expres-
sion to 137% of control. There was also an increase in
mRNA levels of the GDPD isoenzymes GDPD2 and
GDPD3 in the microarray; however, neither of these forms
is known to be specific for GPC. No significant changes
were found in the microarray for any of the lysophospholi-
pase isoenzymes.
17-AAG leads to an increase in PC levels at physiological
choline concentration
Choline is transported into the cell by several choline
transporters, each with different affinities for choline and
differing activities over a range of choline concentrations
[34,35]. Therefore, the overall rate of transport of choline
into the cell may depend on the extracellular choline
concentration. Since changes in expression of only one
transporter were observed, we questioned whether 17-
AAG would have the same effect on PC levels when
extracellular choline concentrations are near physiologi-
cal levels (more closely mimicking in vivo conditions). To
address this question, MCF-7 cells were cultured in med-
ium containing 10 μM choline (the concentration in
human plasma) during the 48-hour treatment period
[42,43].
31P and
1H MR spectra showed an increase in PC
Brandes et al. Breast Cancer Research 2010, 12:R84
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Page 9 of 14Table 1 Summary of microarray data for enzymes associated with choline metabolism
Enzyme type Gene
symbol
Gene title Percentage
control
FDR
Choline transport SLC5A7 Solute carrier family 5 (choline transporter), member 7 101 0.91
SLC44A1 Solute carrier family 44, member 1 154
a 2.10 × 10
-6
SLC22A1 Solute carrier family 22 (organic cation transporter),
member 1
99 0.97
SLC22A2 Solute carrier family 22 (organic cation transporter),
member 2
97 0.81
Choline kinase CHKA Choline kinase alpha 109 0.2
CHKB Choline kinase beta 102 0.86
CTP:PC cytidylyltransferase PCYT1A Phosphate cytidylyltransferase 1, choline, alpha 101 0.92
PCYT1B Phosphate cytidylyltransferase 1, choline, beta 109 0.35
Diacylglycerol choline-
phosphotransferase
CHPT1 Choline phosphotransferase 1 146
a 2.4 × 10
-4
Phospholipase A PLA1A Phospholipase A1 member A 121
a 0.05
PLA2G1B Phospholipase A2, group IB (pancreas) 105 0.67
PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) 101 0.96
PLA2G2C Phospholipase A2, group IIC 104 0.83
PLA2G2D Phospholipase A2, group IID 98 0.83
PLA2G2E Phospholipase A2, group IIE 98 0.91
PLA2G3 Phospholipase A2, group III 99 0.18
PLA2G4C Phospholipase A2, group IVC (cytosolic, calcium-
independent)
75
a 0.0043
PLA2G4E Phospholipase A2, group IVE 101 0.95
PLA2G4F Phospholipase A2, group IVF 82
a 0.018
PLA2G5 Phospholipase A2, group V 97 0.87
PLA2G6 Phospholipase A2, group VI (cytosolic, calcium-
independent)
129 0.0067
PLA2G7 Phospholipase A2, group VII 112 0.3
PLA2G10 Phospholipase A2, group X 712
a 1.60 × 10
-8
PLA2G12A Phospholipase A2, group XIIA 87
a 0.03
PLA2G12B Phospholipase A2, group XIIB 106 0.51
PLA2G15 Phospholipase A2, group XV 139 0.00043
PLA2G16 Phospholipase A2, group XVI 131 0.0021
Phospholipase PLD1 Phospholipase D1, phosphatidylcholine-specific 137
a 0.0038
PLD2 Phospholipase D2 106 0.68
PLD3 phospholipase D family, member 3 179
a 7.80 × 10
-7
PLD4 Phospholipase D family, member 4 106 0.68
PLD5 Phospholipase D family, member 5 116 0.1
PLD6 Phospholipase D family, member 6 82
a 0.0036
Lysophospholipase LYPLA1 Lysophospholipase I 90 0.13
LYPLAL1 Lysophospholipase-like 1 88 0.18
LYPLA2 Lysophospholipase II 90 0.14
Glycero phosphocholin
phosphodiesterase
GDPD1 Glycerophosphodiester phosphodiesterase domain
containing 1
106 0.64
GDPD2 Glycerophosphodiester phosphodiesterase domain
containing 2
228
a 1.2 × 10
-6
GDPD3 Glycerophosphodiester phosphodiesterase domain
containing 3
142
a 2.6 × 10
-7
GDPD5 Glycerophosphodiester phosphodiesterase domain
containing 5
116 0.18
GDE1 Glycerophosphodiester phosphodiesterase 1 112 0.062
aThese enzymes had a statistically significant (false discovery rate [FDR] less than or equal to 0.05) modulation in expression with 17-allyamino-17-
demethoxygeldanamycin (17-AAG) treatment.
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Page 10 of 14levels to 202% ± 35% of control with 17-AAG treatment,
from 17.0 ± 3.0 fmol/cell in control cells to 34.3 ± 4.0
fmol/cell in treated cells (n =3 ,P = 0.005). There was
also a significant increase in GPC levels to 214% ± 30% of
control with 17-AAG treatment, from 3.7 ± 0.3 fmol/cell
in control cells to 8.0 ± 1.7 fmol/cell in treated cells (n =
3, P = 0.04). Finally, intracellular choline levels were
elevated to 194% ± 81% of control with treatment, from
1.1 ± 0.5 fmol/cell in control cells to 2.1 ± 0.8 fmol/cell
in 17-AAG-treated cells, although this change did not
reach statistical significance (n =3 ,P = 0.15). Thus, the
effect of 17-AAG on choline-containing metabolite levels
was comparable (within experimental error) in cells cul-
tured at physiological choline concentrations and cells
cultured with 56 μM choline.
Discussion
In our study, we examined the effects of Hsp90 inhibi-
tion on choline metabolism by treating MCF-7 breast
cancer cells with the clinically relevant Hsp90 inhibitor,
17-AAG. We found that 17-AAG treatment of MCF-7
cells results in increases in intracellular choline, PC, and
GPC concentrations at both normal cell culture and
physiological extracellular choline concentrations. We
also found that the most significant effect of 17-AAG
on the enzymes associated with choline metabolism was
an upregulation in expression of choline transporter
SLC44A1 and PLA2.
In mammalian cells, choline is actively transported
i n t ot h ec e l lb yv a r i o u so r g a n i cc a t i o nt r a n s p o r t e r s
[34,35]. The four main proteins responsible for choline
transport in human cells are SLC5A7 (high-affinity cho-
line transporter), SLC44A1 (intermediate-affinity choline
transporter-like protein), and SLC22A1 and SLC22A2
(polyspecific organic-cation transporters with a very low
affinity for choline). SLC44A1 is ubiquitously expressed
in human tissues, implying that it is involved in choline
metabolism for a broad purpose, such as phospholipid
synthesis [44-47]. In MCF-7 cells, SLC44A1 is the most
commonly expressed choline transporter (and mRNA
expression levels are 2- to 3-fold higher than SLC22A1/
2 and more than 30-fold higher than SLC5A7 [16]) and
is localized on both the plasma and mitochondrial mem-
branes [48]. In our study, 17-AAG did not cause signifi-
cant changes in SLC5A7, SLC22A1, or SLC22A2 but
did significantly increase expression of SLC44A1. Cho-
line transport has been shown to be the rate-limiting
step in the two-step formation of PC in breast cancer
cell lines, including MCF-7 [49]. Since transport of cho-
line into the cells is slower than phosphorylation of cho-
line, an increase in choline transport would result in an
increase in the synthesis of PC. Indeed, in our study, no
significant changes in ChoK expression or activity were
observed following 17-AAG treatment, ruling out the
contribution of ChoK to the increased PC pool. The
overexpression of choline transporter SLC44A1 is thus
the most likely explanation for an increase in choline
transport into the cell, and this would result in
increased intracellular choline and de novo synthesis of
PC following 17-AAG treatment.
The link between Hsp90 inhibition and increased
SLC44A1 expression remains to be determined. Hsp90
is a chaperone protein with an extremely wide range of
client proteins, including those with critical roles in sig-
nal transduction, cellular trafficking, chromatin remodel-
ing, cell growth, differentiation, and reproduction [50].
With such a global effect on protein and gene expres-
sion, the metabolic changes observed could be due to a
wide variety of causes. Studies on SLC44A1 are limited,
with some indications that Sp1 or glucocorticoid recep-
tor or both may play a role in its transcription [51-54].
However, neither of these transcription factors likely
mediates the effect observed here, since both were
reported to require active Hsp90 for their function and
since treatment with the 17-AAG analogue geldanamy-
cin abrogates their transcriptional activity [53,55].
Further studies are necessary to link the effect of Hsp90
to the regulation of choline transport.
Aside from the de novo synthesis of PC, two other
potential mechanisms could contribute to PC accumula-
tion: a decrease in the further metabolism of PC via
CCT and an increase in the breakdown of PtdCho. We
found no significant change in CCT expression or activ-
ity. Although CCT activity can be modulated by relocali-
zation [56] or by changes in substrate concentration, the
biological assay findings are consistent with the MRS
data, in which there was no modulation in total PtdCho
levels. This result is also in line with the fact that CCT
is considered the overall rate-limiting step in the synth-
esis of PtdCho [36]. With regard to the breakdown of
PtdCho, the expression of PLD increased to 137% fol-
lowing treatment. PLD could generate additional intra-
cellular choline and possibly contribute to PC synthesis.
However, the fact that essentially the entire intracellular
choline pool was labeled following 48 hours of exposure
to labeled choline makes this contribution unlikely. The
activity of PLC, which could directly generate PC,
dropped following 17-AAG treatment to 66% ± 10% of
control. Thus, although modulation of the phospholi-
pases could theoretically have a contribution to the
increase in PC, the live cell and extract MRS data show-
ing increases in total PC and de novo PC synthesis to
the same extent, along with mRNA expression showing
increased SLC44A1 expression to a similar degree, favor
an increase in choline transport as the primary mechan-
ism for increased intracellular choline and PC.
Regarding the observed increase in total and de novo
GPC following 17-AAG treatment, we observed an
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microarray data showed an increase in five of the PLA2
isoenzymes. Thus, the increase in GPC is likely due to
increased PtdCho breakdown in treated cells. Activation
of PLA2 was also observed in response to other types of
therapy [33]. However, we did not observe a significant
change in total PtdCho levels. One possible explanation
could be a lack of sensitivity: the concentration of
PtdCho (25 ± 4 fmol/cell in control cells) is about five
times greater than the concentration of GPC (4 ± 1
fmol/cell in control cells), and the change in GPC con-
centration from control to treated cells (an increase of
3.3 fmol/cell) is smaller than the standard deviation in
the total PtdCho concentration. It is thus possible that
our methods are not sensitive enough to detect such a
small change. Alternatively, it is possible that inhibition
of PLC (17-AAG caused PLC activity to decrease to 66%
± 10% of control) functions to counteract the elevated
breakdown of PtdCho by PLA2, thereby maintaining a
constant PtdCho pool.
Our findings are in agreement with those of the pre-
vious studies performed by Chung and colleagues [29]
on human colon cancer cell lines, which reported an
increase in PC concentrations in both cells and tumors
when probed either with
31Po r
1H MRS. Additionally,
our results are in line with an increase in uptake of the
PET tracer [
11C]-choline reported in MCF-7 cells fol-
lowing Hsp90 inhibition [30]. This study, which mea-
sured choline uptake after cells were exposed to [
11C]-
choline for 30 minutes, supports our results that inhibi-
tion of Hsp90 causes an increase in the transport of
choline. An increase in [
11C]-choline uptake was also
reported in human glioblastoma and human colon can-
cer cell lines, indicating that the mechanistic findings
described here could potentially explain the metabolic
effect of 17-AAG in other cancer cell types.
In contrast, Le and colleagues [57] reported a decrease
in t-Cho levels of prostate cancer xenografts during the
first 48 hours of treatment with 17-AAG, as measured
by
1HM R S I .S i n c et h i sw a st h ef i r s ti n v e s t i g a t i o no f
choline-containing metabolite levels following Hsp90
inhibition in a prostate cancer model, it is possible that
this cancer type responds differently to Hsp90 inhibi-
tion. It is also possible that a longer treatment time is
necessary to cause an increase in the concentration of
PC. Indeed, the drop in PC reported by Le and collea-
gues was observed within 4 hours of treatment. Simi-
larly, Liu and colleagues [58] reported that treatment
with the Hsp90 inhibitor geldanamycin resulted in a
drop in PC and a reduction in (methyl-
14C) choline
uptake within 1 hour of treatment. These rapid changes
i nc h o l i n eu p t a k ea r eu n l i k e l yt oi n v o l v eac h a n g ei n
protein expression, as was the case in our longer study.
Conclusions
We have shown in our study, for the first time in a
breast cancer model, that inhibition of Hsp90 results in
a significant, MRS-detectable increase in intracellular
choline, PC, and GPC. 17-AAG is currently being
assessed in multiple clinical trials involving breast can-
cer patients, including patients who develop resistance
to other therapies [2,5,59-61]. As Hsp90 inhibitors enter
routine clinical use, the value of MRS as a noninvasive
and localized imaging method to probe the effects of
17-AAG (and possibly other Hsp90 inhibitors) should
thus be assessed further.
1HM R S Ii sa ni n c r e a s i n g l y
recognized imaging method that provides metabolic
information that can help distinguish between benign
and malignant lesions and inform on tumor response to
treatment [62,63]. The t-Cho peak, which is detectable
by
1H MRSI, is comprised of choline, PC, and GPC. The
substantial increase in all three metabolites observed in
this study would thus provide an easily detectable non-
invasive biomarker of molecular drug response, which
could enhance treatment monitoring and contribute to
improved care for breast cancer patients.
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